Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines
| Verfasser: | |
|---|---|
| Dokumenttyp: | Artikel |
| Erscheinungsdatum: | 2017 |
| Reihe/Periodikum: | Value in Health ; volume 20, issue 10, page 1260-1269 ; ISSN 1098-3015 |
| Verlag/Hrsg.: |
Elsevier BV
|
| Schlagwörter: | Public Health / Environmental and Occupational Health / Health Policy |
| Sprache: | Englisch |
| Permalink: | https://search.fid-benelux.de/Record/base-27409341 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | http://dx.doi.org/10.1016/j.jval.2017.05.013 |
